Rein Therapeutics, Inc. (RNTX)

Rein Therapeutics, Inc. is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory lung diseases. The company was previously known as Aileron Therapeutics and adopted the Rein name after acquiring Lung Therapeutics. It is based in Austin, Texas.

Its lead program, LTI-03, is an inhaled peptide being developed for idiopathic pulmonary fibrosis, a progressive scarring disease of the lungs. The drug candidate is designed to protect the cells lining the lung's air sacs and to limit fibrotic activity. The company's pipeline also includes other candidates aimed at fibrosis-related conditions.